Through a series of comprehensive approaches, we demonstrated that the upregulated BIRC5 expression is strongly associated with clinicopathologic features, adverse clinical outcomes, and immune cell infiltration in low-grdae glioma. The gene discussed is BIRC5; the disease is glioma.